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Coronavirus Disease 2019 (COVID-19)
Information for Pediatric Healthcare Providers
Burden of COVID-19 and epidemiologic risk factors in
children
Relatively few cases of COVID-19 caused by SARS-CoV-2 infection have been reported in children compared with the total
number of cases in the general population. As of Feb. 20, 2020, 2.4% of the 75,465 cases (confirmed and suspected) in
China had occurred among persons younger than 19 years old. An analysis from one large city in southern China
suggests that, among all cases, the proportion of children younger than 15 years old may have increased from 2% to 13%
from early to later in the outbreak.
Of the cases reported in China to date, most children had exposure to household members with confirmed COVID-19. In
one case, a three-month-old child visited a healthcare setting before COVID-19 was confirmed and was thought to be the
first case in a family cluster—the source of infection (healthcare or community) was not determined. At least one child
who primarily had gastrointestinal symptoms sought care at multiple outpatient healthcare centers before becoming a
confirmed case.
During previous outbreaks caused by related zoonotic beta coronaviruses, Severe Acute Respiratory Syndrome (SARS)
and Middle Eastern Respiratory Syndrome (MERS), the majority of confirmed cases occurred among adults. During the
2002-2003 SARS epidemic, less than 5% of cases were diagnosed in patients younger than 18. The majority of SARS cases
in patients younger than 18 were thought to have occurred through household transmission, though some cases were
hospital-acquired. The majority of MERS-CoV cases in children were also thought to be due to household transmission.
Children may play a role in the spread of SARS-CoV-2 in the community. In one report examining 10 infected children in
China, SARS-CoV-2 ribonucleic acid (RNA) was detected in respiratory specimens up to 22 days after symptoms began and
in stool up to 30 days after symptoms began. A case report of a 6-month-old infant describes detection of SARS-CoV-2
RNA in blood, stool, and multiple nasopharyngeal swab samples, even though the infant’s only documented
manifestation of illness was one recorded temperature of 38.5° C (101.3° F). Viral culture was not performed on
specimens in these reports; therefore, it is uncertain whether persistent or asymptomatic RNA detection represented
potentially transmissible virus.
Currently, it is unknown if differences in reported incidence of confirmed COVID-19 among children versus adults in
China is because of difference in exposures (e.g., children are less likely to care for sick contacts), disease severity, testing,
or surveillance (e.g., symptoms at presentation differ from case definitions for surveillance or diagnosis).
Who this is for: Pediatric Healthcare Providers
What this is for: To inform pediatric healthcare providers of information available on children with COVID-19.
How to use: Refer to this information when managing pediatric patients with confirmed or suspected COVID-19.
Clinical presentation in children
The predominant signs and symptoms of COVID-19 reported to date among all patients are similar to other viral
respiratory infections. These include fever, cough, and difficulty breathing. Gastrointestinal symptoms, including
abdominal pain, diarrhea, nausea, and vomiting, were reported in a minority of adult patients.
In a report of nine hospitalized infants in China with confirmed COVID-19, only half presented with fever. At least one
child to date had primarily gastrointestinal symptoms of vomiting, diarrhea, and anorexia at initial presentation. There
have been multiple reports to date of children with asymptomatic SARS-CoV-2 infection.
Data from pediatric cases of SARS and MERS also show milder symptoms among children compared with adults, and
adolescents with SARS had more severe symptoms compared with younger children. Co-detection of other respiratory
pathogens (influenza, respiratory syncytial virus, Mycoplasma pneumoniae) have been described in children with COVID-
19.
Clinical course and complications in children
Complications of COVID-19 appear to be milder among children compared with adults based on limited reports from
China. Severe complications (e.g., acute respiratory distress syndrome, septic shock) were reported in one case of a 13-
month old with confirmed COVID-19. Other reports describe a mild disease course, including in infants. As of February 20,
2020, just one of the 2,114 deaths among 55,924 confirmed COVID-19 cases in China occurred among children younger
than 20 years old. No further details were provided about this patient.
Chest X-rays of children with COVID-19 show patchy infiltrates consistent with viral pneumonia, and chest CT scans have
shown nodular ground glass opacities.
Symptoms in Pediatric Patients
Illness among pediatric cases appear to be mild, with most cases presenting with:
symptoms of respiratory infection
cough
nasal congestion
rhinorrhea
sore throat
Signs and symptoms of COVID-19 in children may be similar to those for common viral respiratory infections or
other childhood illnesses. It is important for pediatric providers to have an appropriate suspicion of COVID-19, but
also to continue to consider and test for other diagnoses, such as influenza (see CDC’s Flu Information for
Healthcare Professionals for more information).
During the 2003-2004 SARS outbreak, patients younger than 12 years old had milder and shorter illnesses than adults,
and no deaths were reported. Death was rare among children with MERS. One pediatric death from MERS was reported
in a child with cystic fibrosis who had respiratory specimens also positive for influenza A(H1N1)pdm09 and multidrug-
resistant Pseudomonas.
Though symptoms and disease course for COVID-19 may be milder in children than adults, it is unknown if children with
underlying medical conditions are at increased risk of severe disease.
Treatment and prevention
Currently, there are no antiviral drugs recommended or licensed by the U.S. Food and Drug Administration (FDA) for
COVID-19. Clinical management includes promptly using recommended infection prevention and control measures (e.g.,
a respirator or facemask, gloves, gown, eye protection) in healthcare settings and supportive management of
complications.
Additional information
For general information on caring for patients with confirmed or possible COVID-19 please see: What Healthcare
Personnel Should Know about Caring for Patients with Confirmed or Possible COVID-19 Infection
For CDC’s latest clinical guidance for management of patients with COVID-10 please see: Interim Clinical Guidance for
Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19)
For information on infection prevention and control recommendations, please see: Interim Infection Prevention and
Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under
Investigation for COVID-19 in Healthcare Settings
For information on COVID-19 and pregnancy, please see: Frequently Asked Questions and Answers: Coronavirus Disease
2019 (COVID-19) and Pregnancy
For information on COVID-19 and breastfeeding, please see: Interim Guidance on Breastfeeding for a Mother Confirmed
or Under Investigation For COVID-19
For information for healthcare facilities on how to prepare for the COVID-19 outbreak: Steps Healthcare Facilities Can
Take Now to Prepare for Coronavirus Disease 2019 (COVID-19)
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